Transcenta Therapeutics announced a non‑exclusive license of its highly intensified continuous bioprocessing (HiCB) platform to Taiwan CDMO EirGenix, including continuous perfusion and hybrid continuous purification processes plus regulatory support packages. Transcenta will receive upfront, milestone and potential royalty payments. EirGenix plans to adopt HiCB for CDMO clients pursuing intensified biologics manufacturing. Transcenta’s CEO framed the deal as a way to expand global access and fund R&D; the agreement underscores a broader industry shift toward continuous manufacturing to cut cost of goods and accelerate biologics scale‑up for commercial supply.